CAS NO: | 56420-45-2 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibitingTopoisomerase[1]. Epirubicin inhibits DNA and RNA synthesis. Epirubicin is aForkhead box protein p3 (Foxp3)inhibitor and inhibits regulatory T cell activity[2]. | |
IC50& Target[1] |
| |
体外研究 (In Vitro) | Epirubicin (4'-Epidoxorubicin), like doxorubicin, exerts its antitumor effects by complex with DNA, resulting in damage to DNA and interference with the synthesis of DNA, RNA, and proteins. Epirubicin may also affect the integrity and activity of cellular membranes. Maximal cell kill caused by Epirubicin occurs during the S phase of the cell cycle. With higher concentrations effects are also seen in early G2 as well as G1 and M phases[1]. | |
体内研究 (In Vivo) | Epirubicin (4'-Epidoxorubicin) are clinically active against a broad range of tumor types, including breast cancer, malignant lymphomas, soft tissue sarcomas, lung cancer, pleural mesothelioma, gastrointestinal cancer, head and neck cancer, ovarian cancer, prostatic carcinoma, transitional bladder carcinoma and so on[4]. | |
Clinical Trial | ||
分子量 | 543.52 | |
Formula | C27H29NO11 | |
CAS 号 | 56420-45-2 | |
中文名称 | 表阿霉素;表柔比星 | |
运输条件 | Room temperature in continental US; may vary elsewhere. | |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |